Properties of Special Biomarkers in Immunological Studies of Systemic Scleroderma
Keywords:
Systemic scleroderma, Siglec-1, biomarker, immune system, inflammationAbstract
Scleroderma is a connective tissue disease characterized by damage to small and large vessels, inflammation, autoimmune disease, and tissue remodeling. This article analyzes the properties of the Siglec-1 biomarker in the immunological processes of systemic scleroderma. Siglec-1 is a type of lectin that binds to sialic acids, which plays an important role in the immune system and inflammatory processes. In systemic scleroderma, cells that highly express this biomarker, macrophages and dendritic cells, are important in controlling the inflammatory and fibrotic processes in the development of the disease. The diagnostic and prognostic properties of Siglec-1 help in identifying and predicting the early stages of the disease. Also, the therapeutic potential of Siglec-1 opens up the possibility of developing new treatments to modulate autoimmune inflammation in systemic scleroderma and prevent the development of fibrosis.
References
Бабамурадова З. Б., Шавази Н. Н. Оценка эффективности и безопасности биологических препаратов при ревматоидном артрите //Журнал перспективных медицинских и стоматологических исследований. – 2021. – Т. 9. – №. 6. – С. 26-31.
Шодикулова Г. З., Бабамурадова З. Б. Клинико-лабораторные показатели и их взаимосвязь с уровнем магния при недифференцированной дисплазией соединительной ткани //Достижения науки и образования. – 2019. – №. 10 (51). – С. 41-45.
Шодикулова Г. З., Шоназарова Н. Х. Особенности заболевания щитовидной железы у больных ревматоидным артритом с кардиометаболическим синдромом //Journal of cardiorespiratory research. – 2022. – Т. 1. – №. 2. – С. 22-25.
Allanore, Y.; Simms, R.; Distler, O.; Trojanowska, M.; Pope, J.; Denton, C.P.; Varga, J. Systemic sclerosis. Nat. Rev. Dis. Prim. 2015, 1, 15002. [CrossRef] [PubMed]
Denton, C.P.; Khanna, D. Systemic sclerosis. Lancet 2017, 390, 1685–1699. [CrossRef]
Aringer, M.; Costenbader, K.; Daikh, D.; Brinks, R.; Mosca, M.; Ramsey-Goldman, R.; Smolen, J.S.; Wofsy, D.; Boumpas, D.T.; Kamen, D.L.; et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019, 71, 1400–1412. [CrossRef]
Babamurodova Z. B. Revmatoid artrit kasalligida sitokinlar tizimi vazifasining molekular asoslari va anti-sitokinli davolash mexanizmi //Журнал гуманитарных и естественных наук. – 2023. – №. 4 [2]. – С. 131-136.
Bakhtiyarovna B. Z., Marufovna A. D., Nuraliyevich S. R. Evaluation of immunological parameters of patients with osteoarthrosis //American Journal of Interdisciplinary Research and Development. – 2022. – Т. 5. – С. 294-298.
Brkic, Z.; van Bon, L.; Cossu, M.; van Helden-Meeuwsen, C.G.; Vonk, M.C.; Knaapen, H.; Berg, W.V.D.; A Dalm, V.; Van Daele, P.L.; Severino, A.; et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann. Rheum. Dis. 2015, 75, 1567–1573. [CrossRef]
Burmester, G.R.; Blanco, R.; Charles-Schoeman, C.; Wollenhaupt, J.; Zerbini, C.; Benda, B.; Gruben, D.; Wallenstein, G.; Krish- naswami, S.; Zwillich, S.H.; et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet 2013, 381, 451–460. [CrossRef]
Cohen, T. J., et al. (2015). Siglec-1 and its role in inflammatory responses in systemic sclerosis. Journal of Autoimmunity, 59, 42-53.
Ciechomska, M.; Skalska, U. Targeting interferons as a strategy for systemic sclerosis treatment. Immunol. Lett. 2018, 195, 45–54.
Ciechomska, M.; Cant, R.; Finnigan, J.; van Laar, J.M.; O’Reilly, S. Role of toll-like receptors in systemic sclerosis. Expert Rev. Mol. Med. 2013, 15, e9.
Ewu, M.; Eassassi, S. The Role of Type 1 Interferon in Systemic Sclerosis. Front. Immunol. 2013, 4, 266. [CrossRef]
Furie, R.; Khamashta, M.; Merrill, J.T.; Werth, V.P.; Kalunian, K.; Brohawn, P.; Illei, G.G.; Drappa, J.; Wang, L.; Yoo, S. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017, 69, 376–386. [CrossRef]
Graf, M.; von Stuckrad, S.L.; Uruha, A.; Klotsche, J.; Zorn-Pauly, L.; Unterwalder, N.; Buttgereit, T.; Krusche, M.; Meisel, C.; Burmester, G.R.; et al. SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open 2022, 8, e001934. [CrossRef]
Guo, X.; Higgs, B.; Bay-Jensen, A.C.; Karsdal, M.A.; Yao, Y.; Roskos, L.K.; White, W.I. Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis. J. Investig. Dermatol. 2015, 135, 2402–2409. [CrossRef]
Sgonc, R., et al. (2013). Role of macrophages and dendritic cells in systemic sclerosis pathogenesis: Implications for therapeutic targeting. Immunology and Cell Biology, 91(1), 41-49.
Karalilova, R.V.; Batalov, Z.A.; Sapundzhieva, T.L.; Matucci-Cerinic, M.; Batalov, A.Z. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol. Int. 2021, 41, 1743–1753.
Kay, J.; Upchurch, K.S. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 2012, 51 (Suppl. 6), vi5–vi9.
Kubo, S.; Nakayamada, S.; Sakata, K.; Kitanaga, Y.; Ma, X.; Lee, S.; Ishii, A.; Yamagata, K.; Nakano, K.; Tanaka, Y. Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Front. Immunol. 2018, 9, 1510.
Lerkvaleekul, B.; Veldkamp, S.R.; van der Wal, M.M.; Schatorjé, E.J.H.; Kamphuis, S.S.M.; Berg, J.M.V.D.; Muller, P.C.E.H.; Armbrust, W.; Vastert, S.J.; Wienke, J.; et al. Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology 2021, 61, 2144–2155.
Lundberg, I.E.; Tjärnlund, A.; Bottai, M.; Werth, V.P.; Pilkington, C.; De Visser, M.; Alfredsson, L.; A Amato, A.; Barohn, R.J.; Liang, M.H.; et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann. Rheum. Dis. 2017, 76, 1955–1964.
Melsens, K.; De Keyser, F.; Decuman, S.; Piette, Y.; Vandecasteele, E.; Smith, V. Disease activity indices in systemic sclerosis: A systematic literature review. Clin. Exp. Rheumatol. 2016, 34, 186–192.
Muskardin, T.L.W.; Niewold, T.B. Type I interferon in rheumatic diseases. Nat. Rev. Rheumatol. 2018, 14, 214–228. [CrossRef] [PubMed]
Morand, E.F.; Furie, R.; Tanaka, Y.; Bruce, I.N.; Askanase, A.D.; Richez, C.; Bae, S.-C.; Brohawn, P.Z.; Pineda, L.; Berglind, A.; et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. N. Engl. J. Med. 2020, 382, 211–221.
Choi, Y. K., et al. (2018). Diagnostic value of Siglec-1 in systemic sclerosis patients: Correlation with disease activity and fibrosis severity. Rheumatology International, 38(8), 1475-1482.
Ortega-Hernandez, O.-D.; Shoenfeld, Y. Mixed connective tissue disease: An overview of clinical manifestations, diagnosis and treatment. Best Pract. Res. Clin. Rheumatol. 2012, 26, 61–72.
Pillai, S.; Netravali, I.A.; Cariappa, A.; Mattoo, H. Siglecs and Immune Regulation. Annu. Rev. Immunol. 2012, 30, 357–392.
Psarras, A.; Emery, P.; Vital, E. Type I interferon-mediated autoimmune diseases: Pathogenesis, diagnosis and targeted therapy. Rheumatology 2017, 56, 1662–1675.
Rose, T.; Szelinski, F.; Lisney, A.; Reiter, K.; Fleischer, S.J.; Burmester, G.R.; Radbruch, A.; Hiepe, F.; Grützkau, A.; Biesen, R.; et al. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren’s syndrome. RMD Open 2016, 2, e000292.
Rose, T.; Grützkau, A.; Klotsche, J.; Enghard, P.; Flechsig, A.; Keller, J.; Riemekasten, G.; Radbruch, A.; Burmester, G.-R.; Dörner, T.; et al. Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology 2017, 56, 1618–1626.
Sacre, K.; A Criswell, L.; McCune, J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res. Ther. 2012, 14, R155.
Siegert, E.; Uruha, A.; Goebel, H.-H.; Preuße, C.; Casteleyn, V.; Kleefeld, F.; Alten, R.; Burmester, G.R.; Schneider, U.; Höppner, J.; et al. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol. 2021, 141, 917–927.
Skaug, B.; Assassi, S. Type I interferon dysregulation in Systemic Sclerosis. Cytokine 2019, 132, 154635.
Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann. Rheum. Dis. 2017, 69, 35–45.
Van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A., Jr.; Carreira, P.E.; et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann. Rheum. Dis. 2013, 72, 1747–1755.
Von Stuckrad, S.L.; Klotsche, J.; Biesen, R.; Lieber, M.; Thumfart, J.; Meisel, C.; Unterwalder, N.; Kallinich, T. SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus. Lupus 2020, 29, 1914–1925.
Wu, Y.; Guo, Q.; Gong, X.; Sun, W.; Zhang, W.; Zhao, W.; Yang, Y.; Fan, C.; Li, Y.; Teng, W.; et al. Increased expression of Siglec-1 on peripheral blood monocytes and its relationship with inflammatory reaction in autoimmune thyroiditis. Chin. J. Endocrinol. Metab. 2019, 12, 99–104.
Xiong, Y.-S.; Cheng, Y.; Lin, Q.-S.; Wu, A.-L.; Yu, J.; Li, C.; Sun, Y.; Zhong, R.-Q.; Wu, L.-J. Increased expression of Siglec-1 on peripheral blood monocytes and its role in mononuclear cell reactivity to autoantigen in rheumatoid arthritis. Rheumatology 2013, 53, 250–259.
Baxtiyarovna B. Z., Zikriyaevna S. G., Ismailovna I. F. Immunological Characteristics of The Useful Biomarker Siglec-1 For the Differential Diagnosis of Systemic Scleroderma //NATURALISTA CAMPANO. – 2024. – Т. 28. – №. 1. – С. 3037-3042.
Bakhtiyarovna B. Z., Marufovna A. D., Nuraliyevich S. R. EVALUATION OF IMMUNOLOGICAL PARAMETERS OF PATIENTS WITH OSTEOARTHROSIS //American Journal of Interdisciplinary Research and Development. – 2022. – Т. 5. – С. 294-298.
Kizi, S. I. K., & Babamuradova, Z. B. (2023). IMMEDIATE OUTCOMES OF UNSTABLE ANGINA IN METABOLIC SYNDROME. International Journal of Medical Sciences And Clinical Research, 3(02), 44-49.
Ismailovna, I. F., Zikriyayevna, S. G., & Bakhtiyarovna, B. Z. (2024). Assessment of the Significance of Diagnostic Criteria in Rheumatoid Arthritis. NATURALISTA CAMPANO, 28(1), 2995-3001.
Babamuradova, Z. B., Shavazi, N. N., Turkmanov, M. M., Ochilova, M. S., & Nuralievich, R. S. (2023). RELEVANCE AND PROSPECTS OF BIOLOGIC THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Chelonian Research Foundation, 18(2), 49-63.
